Related Experiment Video
Updated: Dec 12, 2025
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Should we screen patients with hematologic malignancies for COVID-19?
Elie Rassy1, Rita-Maria Khoury-Abboud1, Nathalie Ibrahim1
1Hematology and Oncology Department, Saint Joseph University, Lebanon.
Insights
This review discusses screening strategies for COVID-19 in patients with hematologic malignancies. It covers the rationale, diagnostic tools, and guidelines for managing these vulnerable patients during the pandemic.
Area of Science:
- Hematology
- Infectious Diseases
- Oncology
Background:
- The COVID-19 pandemic created significant challenges for managing patients with hematologic malignancies.
- Hematology guidelines differed from oncology, recommending individualized treatment rather than universal delays.
Purpose of the Study:
- To review the pathophysiology of COVID-19.
- To explore the rationale for screening hematologic malignancy patients for COVID-19.
- To discuss available screening tools and guidelines.
Main Methods:
- Literature review on COVID-19 pathophysiology.
- Analysis of existing guidelines for hematologic malignancy patient care during pandemics.
- Evaluation of diagnostic tools for COVID-19 screening.
Main Results:
- Hematologic malignancy patients are at high risk for severe COVID-19 outcomes.
- Screening allows for continued access to essential treatments while managing infection risk.
- Knowledge of COVID-19 diagnostics is crucial for effective screening protocols.
Conclusions:
- Screening protocols are essential for safely managing hematologic malignancy patients during the COVID-19 pandemic.
- Individualized approaches balancing treatment and infection control are necessary.
- Ongoing research into diagnostics and guidelines will further refine patient care.
Abstract:
The coronavirus disease (COVID-19) pandemic has posed several challenges to the hematology community to re-organize the medical care of patients with hematologic malignancies. Whereas the oncology societies favored a more or less conservative approach which considered the possibility of delaying treatment administration on a case-by-case basis, the hematology community guidelines were less stringent and recommended adequate individualized regimens. As countries are de-escalating the lockdown and the medical community is unable to foresee the end of the current outbreak will and whether the pandemic would eventually come back as a seasonal infection, there is interest in screening of patients with hematology malignancies with COVID-19 instead of limiting access to curative treatments. The rapidly accumulating knowledge about COVID-19 allows a better understanding of the diagnostic tools that may be potentially used in screening. Herein, we briefly review the pathophysiology of COVID-19, the rationale of screening of patients with hematologic malignancies, tools for screening, and available guidelines.
More Related Videos
08:01Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
Published on: March 22, 2012
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
